Estrella Immunopharma (ESLA) vs NewcelX (NCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed NewcelX (NCEL) over the past year, losing 67.9% versus a loss of 83.3%. Over five years, ESLA leads with a -95.8% price change compared with -99.7% for NCEL. Estrella Immunopharma is the larger company by market cap ($18.2 million vs $18.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | NCEL |
|---|---|---|
| Share price | $0.4175 | $3.11 |
| Market cap | $18.16M | $17.96M |
| 1-day change | -0.43% | +2.47% |
| YTD return | -73.24% | +63.68% |
| 1-year return | -67.88% | -83.32% |
| 5-year return | -95.77% | -99.68% |
| P/E ratio (TTM) | — | 5.98 |
| EPS (TTM) | $-0.25 | $0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $18.60 |
| 52-week low | $0.361 | $1.83 |
| Distance from 52-week high | -86.75% | -83.28% |
| Analyst consensus | none | none |
| Avg. price target upside | +2774.25% | +639.55% |
| Average volume | 38.61K | 10.28K |
| Shares outstanding | 43.50M | 5.78M |
| Employees | — | 9 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed NCEL by 15.4 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Healthcare · Biotechnology
About NewcelX
NCEL stock →NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders.
Healthcare · Biotechnology · 9 employees
ESLA vs NCEL FAQ
Which is bigger, Estrella Immunopharma or NewcelX?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $18.16M compared with $17.96M for NewcelX (NCEL).
Which stock has performed better over the past year, ESLA or NCEL?
ESLA returned -67.88% over the past 12 months, compared with -83.32% for NCEL (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and NewcelX in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.